NEW YORK, Sept. 29, 2022 /PRNewswire/ -- The report "Diuretic Drugs Market by Product Type and Geography - Forecast and Analysis 2022-2026" has been added to Technavio's offerings. The market size is anticipated to grow by USD 95.64 million from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 5.44% during the forecast period.

Technavio provides a comprehensive report summary describing the market size and forecast along with research methodology. The FREE sample report is available in PDF format

Market Drivers

The increasing incidence of hypertension due to the increasing pressure on the walls of the arteries is driving the growth of the market. Hypertension raises the risk of diseases such as kidney failure, stroke, and heart disease. It can also affect the brain by causing a stroke, TIA, dementia, or mild cognitive impairment. The prevalence of hypertension in low- and middle-income countries is high. Hypertension has no warning signs or symptoms. Hence, it is also known as the silent killer. It can also cause bone loss, sexual dysfunction, and conditions such as obstructive sleep apnea (OSA). Thus, the rise in the number of patients with hypertension owing to obesity, diabetes, CKD, stress, sedentary lifestyle, and alcohol addiction will drive the growth of the market during the forecast period.

Vendor Landscape

The diuretic drugs market is concentrated, and the vendors are deploying growth strategies such as investments in R&D to compete in the market. The competition among vendors is high owing to the fast-growing sales of some of the diuretic drugs. In addition, a strong pipeline of drugs to treat high blood pressure and edema will intensify the competition further during the forecast period. The market will record the approvals for several promising drugs, which will intensify competition among vendors.

Company Profiles

The diuretic drugs market report includes information on the product launches, sustainability, and prospects of leading vendors including AbbVie Inc., Akorn Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc., Casper Pharma, Hikma Pharmaceuticals Plc, Lannett Co. Inc., Novartis AG, Monarch Pharmachem, Pfizer Inc., Padagis US LLC, Sanofi, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., VITARIS AG, Validus Pharmaceuticals LLC, and Zydus Lifesciences Ltd.

Technavio's reports provide key strategic initiatives used by vendors, along with key news and the latest developments. View our FREE PDF Sample Report Now

Competitive Analysis

The report includes competitive analysis, a proprietary tool to evaluate and analyze the position of companies based on their industry position score and market performance score. The tool uses various factors for categorizing the players into categories such as growth strategies, financial performance over the last three years, new product launches, innovation score, growth in market share, investments, etc.

Market Segmentation
  • By product type, the market has been classified into loop diuretics, thiazide diuretics, and others. The loop diuretic drugs will contribute the largest share of the market during the forecast period.
  • By geography, the market has been classified into North America, Europe, Asia, and Rest of World (ROW). North America will have the largest share of the market during the forecast period.

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a FREE PDF Sample Report

Related Reports

Motion Sickness Drugs Market by Product and Geography - Forecast and Geography 2022-2026: The motion sickness drugs market is projected to grow by USD 119.64 million from 2021 to 2026.

Antihypertensive Drugs Market by Type and Geography - Forecast and Analysis 2022-2026: The antihypertensive drugs market share is expected to increase by USD 5.87 billion from 2021 to 2026.

Diuretic Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 5.44%

Market growth 2022-2026

USD 95.64 million

Market structure

Concentrated

YoY growth (%)

4.29

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 37%

Key consumer countries

US, Canada, Denmark, China, and India

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

AbbVie Inc., Akorn Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc., Casper Pharma, Hikma Pharmaceuticals Plc, Lannett Co. Inc., Monarch Pharmachem, Novartis AG, Padagis US LLC, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Validus Pharmaceuticals LLC, VITARIS AG, and Zydus Lifesciences Ltd.

Market Dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse Health Care Market Reports

Table of Contents

1 Executive Summary

  • 1.1 Market overview 
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Type
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem 
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition 
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis 
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026 
    • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
    • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
    • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
    • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary 
    • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
  • 4.2 Bargaining power of buyers 
    • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
  • 4.3 Bargaining power of suppliers 
    • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants 
    • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes 
    • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry 
    • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
  • 4.7 Market condition 
    • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product Type

  • 5.1 Market segments 
    • Exhibit 24: Chart on Product Type - Market share 2021-2026 (%)
    • Exhibit 25: Data Table on Product Type - Market share 2021-2026 (%)
  • 5.2 Comparison by Product Type 
    • Exhibit 26: Chart on Comparison by Product Type
    • Exhibit 27: Data Table on Comparison by Product Type
  • 5.3 Loop diuretics - Market size and forecast 2021-2026
    • Exhibit 28: Chart on Loop diuretics - Market size and forecast 2021-2026 ($ million)
    • Exhibit 29: Data Table on Loop diuretics - Market size and forecast 2021-2026 ($ million)
    • Exhibit 30: Chart on Loop diuretics - Year-over-year growth 2021-2026 (%)
    • Exhibit 31: Data Table on Loop diuretics - Year-over-year growth 2021-2026 (%)
  • 5.4 Thiazide diuretics - Market size and forecast 2021-2026
    • Exhibit 32: Chart on Thiazide diuretics - Market size and forecast 2021-2026 ($ million)
    • Exhibit 33: Data Table on Thiazide diuretics - Market size and forecast 2021-2026 ($ million)
    • Exhibit 34: Chart on Thiazide diuretics - Year-over-year growth 2021-2026 (%)
    • Exhibit 35: Data Table on Thiazide diuretics - Year-over-year growth 2021-2026 (%)
  • 5.5 Others - Market size and forecast 2021-2026
    • Exhibit 36: Chart on Others - Market size and forecast 2021-2026 ($ million)
    • Exhibit 37: Data Table on Others - Market size and forecast 2021-2026 ($ million)
    • Exhibit 38: Chart on Others - Year-over-year growth 2021-2026 (%)
    • Exhibit 39: Data Table on Others - Year-over-year growth 2021-2026 (%)
  • 5.6 Market opportunity by Product Type 
    • Exhibit 40: Market opportunity by Product Type ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview 
    • Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation 
    • Exhibit 42: Chart on Market share by geography 2021-2026 (%)
    • Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
  • 7.2 Geographic comparison 
    • Exhibit 44: Chart on Geographic comparison
    • Exhibit 45: Data Table on Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
    • Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
    • Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
    • Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
    • Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Europe - Market size and forecast 2021-2026
    • Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
    • Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
    • Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
    • Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • 7.5 Asia - Market size and forecast 2021-2026 
    • Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
    • Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
    • Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
    • Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
    • Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
    • Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
    • Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • 7.7 US - Market size and forecast 2021-2026
    • Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
    • Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
    • Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
    • Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
  • 7.8 Denmark - Market size and forecast 2021-2026
    • Exhibit 66: Chart on Denmark - Market size and forecast 2021-2026 ($ million)
    • Exhibit 67: Data Table on Denmark - Market size and forecast 2021-2026 ($ million)
    • Exhibit 68: Chart on Denmark - Year-over-year growth 2021-2026 (%)
    • Exhibit 69: Data Table on Denmark - Year-over-year growth 2021-2026 (%)
  • 7.9 China - Market size and forecast 2021-2026
    • Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
    • Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
    • Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
    • Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
  • 7.10 Canada - Market size and forecast 2021-2026
    • Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
    • Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
    • Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
    • Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • 7.11 India - Market size and forecast 2021-2026
    • Exhibit 78: Chart on India - Market size and forecast 2021-2026 ($ million)
    • Exhibit 79: Data Table on India - Market size and forecast 2021-2026 ($ million)
    • Exhibit 80: Chart on India - Year-over-year growth 2021-2026 (%)
    • Exhibit 81: Data Table on India - Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity by geography 
    • Exhibit 82: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges 
    • Exhibit 83: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape 
    • Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption 
    • Exhibit 85: Overview on factors of disruption
  • 9.4 Industry risks 
    • Exhibit 86: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered 
    • Exhibit 87: Vendors covered
  • 10.2 Market positioning of vendors 
    • Exhibit 88: Matrix on vendor position and classification
  • 10.3 AbbVie Inc. 
    • Exhibit 89: AbbVie Inc. - Overview
    • Exhibit 90: AbbVie Inc. - Product / Service
    • Exhibit 91: AbbVie Inc. - Key offerings
  • 10.4 Alembic Pharmaceuticals Ltd. 
    • Exhibit 92: Alembic Pharmaceuticals Ltd. - Overview
    • Exhibit 93: Alembic Pharmaceuticals Ltd. - Product / Service
    • Exhibit 94: Alembic Pharmaceuticals Ltd. - Key offerings
  • 10.5 Aurobindo Pharma Ltd. 
    • Exhibit 95: Aurobindo Pharma Ltd. - Overview
    • Exhibit 96: Aurobindo Pharma Ltd. - Product / Service
    • Exhibit 97: Aurobindo Pharma Ltd. - Key offerings
  • 10.6 Hikma Pharmaceuticals Plc 
    • Exhibit 98: Hikma Pharmaceuticals Plc - Overview
    • Exhibit 99: Hikma Pharmaceuticals Plc - Business segments
    • Exhibit 100: Hikma Pharmaceuticals Plc - Key offerings
    • Exhibit 101: Hikma Pharmaceuticals Plc - Segment focus
  • 10.7 Novartis AG 
    • Exhibit 102: Novartis AG - Overview
    • Exhibit 103: Novartis AG - Business segments
    • Exhibit 104: Novartis AG - Key offerings
    • Exhibit 105: Novartis AG - Segment focus
  • 10.8 Pfizer Inc. 
    • Exhibit 106: Pfizer Inc. - Overview
    • Exhibit 107: Pfizer Inc. - Product / Service
    • Exhibit 108: Pfizer Inc. - Key news
    • Exhibit 109: Pfizer Inc. - Key offerings
  • 10.9 Sun Pharmaceutical Industries Ltd. 
    • Exhibit 110: Sun Pharmaceutical Industries Ltd. - Overview
    • Exhibit 111: Sun Pharmaceutical Industries Ltd. - Product / Service
    • Exhibit 112: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 10.10 Teva Pharmaceutical Industries Ltd. 
    • Exhibit 113: Teva Pharmaceutical Industries Ltd. - Overview
    • Exhibit 114: Teva Pharmaceutical Industries Ltd. - Business segments
    • Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key news
    • Exhibit 116: Teva Pharmaceutical Industries Ltd. - Key offerings
    • Exhibit 117: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 10.11 Validus Pharmaceuticals LLC 
    • Exhibit 118: Validus Pharmaceuticals LLC - Overview
    • Exhibit 119: Validus Pharmaceuticals LLC - Product / Service
    • Exhibit 120: Validus Pharmaceuticals LLC - Key offerings
  • 10.12 VITARIS AG 
    • Exhibit 121: VITARIS AG - Overview
    • Exhibit 122: VITARIS AG - Product / Service
    • Exhibit 123: VITARIS AG - Key offerings

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist 
    • Exhibit 124: Inclusions checklist
    • Exhibit 125: Exclusions checklist
  • 11.3 Currency conversion rates for US$ 
    • Exhibit 126: Currency conversion rates for US$
  • 11.4 Research methodology 
    • Exhibit 127: Research methodology
    • Exhibit 128: Validation techniques employed for market sizing
    • Exhibit 129: Information sources
  • 11.5 List of abbreviations 
    • Exhibit 130: List of abbreviations
About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: www.technavio.com/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/diuretic-drugs-market-to-record-a-cagr-of-5-44-increasing-incidence-of-hypertension-among-people-to-drive-growth---technavio-301635779.html

SOURCE Technavio

Originally published on the TownNews Content Exchange.